Press Releases

Investor Relations

Filter by Year

February 24, 2020

Acer Therapeutics Announces ACER-001 for Urea Cycle Disorders Trial Shows Bioequivalence to BUPHENYL®

Anticipate submitting New Drug Application in early 2021 assuming successful completion of additional nonclinical work and 12-month long-term stability data

NEWTON, MA – Feb. 24, 2020 – Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced successful completion and final data from Part B of its pivotal trial evaluating the bioavailability and bioequivalence of […]

Read More